Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical and related industries, reported financial results for Q3 2025. The company posted revenues of $2.0 million for the quarter and $6.9 million for the nine months ended July 31, 2025, compared to $2.4 million and $7.2 million in the respective periods of 2024.
Despite lower revenues, the company reduced its net loss to $0.2 million for Q3 and $0.1 million for the nine-month period, representing improvements of $0.1 million and $0.7 million year-over-year, respectively. Management highlighted strategic initiatives including cost structure optimization and focus on core business segments.
Pharma-Bio Serv (OTCQB:PBSV), una società di consulenza che serve l'industria farmaceutica e settori correlati, ha reso noti i risultati finanziari del terzo trimestre 2025. L'azienda ha registrato ricavi di $2,0 milioni per il trimestre e di $6,9 milioni per i primi nove mesi conclusi il 31 luglio 2025, rispetto a $2,4 milioni e $7,2 milioni nei rispettivi periodi del 2024.
Nonostante i ricavi inferiori, l'azienda ha ridotto la perdita netta a $0,2 milioni per il Q3 e a $0,1 milioni per il periodo di nove mesi, segnando miglioramenti di $0,1 milioni e $0,7 milioni anno su anno, rispettivamente. La direzione ha evidenziato iniziative strategiche tra cui l'ottimizzazione della struttura dei costi e il focus sui segmenti di core business.
Pharma-Bio Serv (OTCQB:PBSV), una firma de consultoría que presta servicios a la industria farmacéutica y sectores relacionados, informó los resultados financieros del tercer trimestre de 2025. La empresa obtuvo ingresos de $2.0 millones en el trimestre y de $6.9 millones en los primeros nueve meses finalizados el 31 de julio de 2025, en comparación con $2.4 millones y $7.2 millones en los respectivos periodos de 2024.
A pesar de los ingresos más bajos, la empresa redujo su pérdida neta a $0.2 millones en el Q3 y a $0.1 millones para el periodo de los nueve meses, lo que representa mejoras de $0.1 millones y $0.7 millones interanual, respectivamente. La dirección destacó iniciativas estratégicas que incluyen la optimización de la estructura de costos y el enfoque en segmentos centrales del negocio.
Pharma-Bio Serv (OTCQB:PBSV)은 의약품 및 관련 산업에 서비스를 제공하는 컨설팅 회사로, 2025년 3분기 재무 실적을 발표했습니다. 회사는 분기에 $2.0 백만의 수익과 2025년 7월 31일 종료된 9개월 동안 $6.9 백만의 수익을 기록했으며, 2024년의 respective 기간에는 각각 $2.4백만, $7.2백만이었습니다.
매출은 감소했지만, 회사는 3분기의 순손실을 $0.2백만, 9개월 동안의 순손실을 $0.1백만으로 줄이며 연간 증가분 $0.1백만, $0.7백만의 개선을 달성했습니다. 경영진은 비용 구조 최적화와 핵심 비즈니스 부문에 집중하는 전략적 이니셔티브를 강조했습니다.
Pharma-Bio Serv (OTCQB:PBSV), une société de conseil au service de l'industrie pharmaceutique et des secteurs connexes, a publié ses résultats financiers pour le T3 2025. L'entreprise a enregistré des revenus de $2,0 millions pour le trimestre et de $6,9 millions pour les neuf mois terminés le 31 juillet 2025, contre $2,4 millions et $7,2 millions pour les périodes respectives de 2024.
Malgré des revenus plus bas, l'entreprise a réduit sa perte nette à $0,2 millions pour le T3 et à $0,1 millions pour la période des neuf mois, ce qui représente des améliorations de $0,1 millions et $0,7 millions en glissement annuel, respectivement. La direction a mis en avant des initiatives stratégiques, notamment l'optimisation de la structure des coûts et le recentrage sur les segments clés de l'activité.
Pharma-Bio Serv (OTCQB:PBSV), eine Beratungsfirma, die die Pharmaindustrie und verwandte Branchen bedient, hat die Finanzergebnisse für das Q3 2025 bekannt gegeben. Das Unternehmen verzeichnete im Quartal Einnahmen von $2,0 Mio. und für die ersten neun Monate bis zum 31. Juli 2025 von $6,9 Mio., verglichen mit $2,4 Mio. bzw. $7,2 Mio. in den jeweiligen Perioden von 2024.
Trotz der geringeren Einnahmen senkte das Unternehmen den Nettoverlust auf $0,2 Mio. im Q3 und auf $0,1 Mio. für den Neunmonatszeitraum, was jährliche Verbesserungen von $0,1 Mio. bzw. $0,7 Mio. bedeutet. Das Management hob strategische Initiativen hervor, einschließlich der Optimierung der Kostenstruktur und der Fokussierung auf Kerngeschäftssegmente.
Pharma-Bio Serv (OTCQB:PBSV)، وهي شركة استشارية تخدم الصناعات الصيدلانية والقطاعات ذات الصلة، أعلنت نتائجها المالية للربع الثالث من عام 2025. سجلت الشركة إيرادات قدرها $2.0 مليون للربع و $6.9 مليون للمدة التسعة أشهر المنتهية في 31 يوليو 2025، مقارنة بـ $2.4 مليون و $7.2 مليون في فترات 2024 المقابلة.
على الرغم من انخفاض الإيرادات، خفضت الشركة صافي خسارتها إلى $0.2 مليون للربع الثالث و< b>$0.1 مليون لفترة التسعة أشهر، مما يمثل تحسنًا بمقدار $0.1 مليون و $0.7 مليون على أساس سنوي على التوالي. وأبرزت الإدارة مبادرات استراتيجية بما في ذلك تحسين هيكل التكاليف والتركيز على قطاعات الأعمال الأساسية.
Pharma-Bio Serv (OTCQB:PBSV)，一家为制药及相关行业提供咨询服务的公司，公布了2025年第三季度的财务业绩。该公司本季度营收为$2.0 百万美元，截至2025年7月31日的前九个月营收为$6.9 百万美元，相比2024年同期的分别为$2.4 百万美元和$7.2 百万美元。
尽管营收下降，该公司将第三季度净亏损降至$0.2 百万美元，前九个月期内净亏损降至$0.1 百万美元，同比分别改善了$0.1 百万美元和$0.7 百万美元。管理层强调包括成本结构优化和聚焦核心业务领域等战略举措。
- Net loss improvement of $0.1M for Q3 and $0.7M for nine months YoY
- Successful implementation of cost structure optimization
- Strategic exit from less profitable business segments
- Multiple significant projects ready for immediate commencement
- Revenue decline of 16.7% to $2.0M in Q3 2025 from $2.4M in Q3 2024
- Nine-month revenue decreased 4.2% to $6.9M from $7.2M YoY
- Continued net loss position of $0.2M in Q3 and $0.1M for nine months
DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately
"Over the past quarters, we have taken decisive steps to streamline our cost structure, prioritize core business segments, and exit less profitable areas. We believe these efforts have positioned the Company to capitalize on new opportunities with greater agility and focus. We are encouraged by the momentum building across our operations and are preparing for the immediate commencement of several significant projects. The Company remains committed to delivering long-term value to shareholders through disciplined execution," stated Mr. Sanchez Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
FAQ
What were Pharma-Bio Serv's (PBSV) Q3 2025 revenue and earnings?
How did PBSV's revenue change in the first nine months of 2025 compared to 2024?
What strategic changes has Pharma-Bio Serv implemented in 2025?
How much did PBSV improve its net loss position in Q3 2025?
